Evidence Based Mental Health, has run workshops around the United Kingdom, organised independently, but often sponsored by pharmaceutical companies. The centre has therefore indirectly received fees and expenses from several of the companies who manufacture antipsychotic drugs. NF has received funds for research, fees, and expenses from several pharmaceutical companies who manufacture antipsychotic drugs and from the Department of Health in England. PH has received support from pharmaceutical companies to attend conferences. He has also received fees for educational lectures to psychiatrists on the psychopharmcology of schizophrenia and on the work described in this paper. PB has received fees for presentations at meetings sponsored by various pharmaceutical companies who manufacture typical and atypical antipsychotics. In addition he is one of the lead investigators of the European schizophrenia cohort funded by Lundbeck. AbstractObjective To discover and explore the factors that result in "false optimism about recovery" observed in patients with small cell lung cancer. Design A qualitative observational (ethnographic) study in two stages over four years. Setting Lung diseases ward and outpatient clinic in university hospital in the Netherlands. Participants 35 patients with small cell lung cancer.

ⅷ Objective To discover and explore the factors that result in the "false optimism about recovery" observed in patients with small cell lung cancer. ⅷ Design A qualitative observational (ethnographic) study in 2 stages over 4 years. ⅷ Setting Lung diseases ward and outpatient clinic in a university hospital in the Netherlands. ⅷ Participants 35 patients with small cell lung cancer. ⅷ Results False optimism about recovery usually developed during the first course of chemotherapy and was most prevalent when the cancer could no longer be seen on x-ray films. This optimism tended to vanish when the tumor recurred, but it could develop again, though to a lesser extent, during further courses of chemotherapy. Patients gradually found out the facts about their poor prognosis, partly by their physical deterioration and partly through contact with fellow patients in a more advanced stage of the illness who were dying. False optimism about recovery was the result of an association between physicians' activism and patients' adherence to the treatment calendar and to the "recovery plot," which allowed them to avoid acknowledging explicitly what they should and could know. The physician did and did not want to pronounce a "death sentence," and the patient did and did not want to hear it. ⅷ Conclusion Solutions to the problem of collusion between physician and patient require an active, patient-oriented approach by the physician. Perhaps solutions have to be found outside the physician-patient relationship itself-for example, by involving "treatment brokers."

The concept of resilience, i.e., the capacity of a system to bounce back after a stressor, is gaining interest across many fields of science, policy and practice. To date, resilience research in people with cognitive decline has predominantly addressed the early stages of decline. We propose that: (1) resilience is a relevant concept in all stages of cognitive decline; and (2) a socioecological, multisystem perspective on resilience is required to advance understanding of, and care and support for people with cognitive decline and their support networks. We substantiate our position with literature and examples. Resilience helps to understand differences in response to risk factors of (further) cognitive decline and informs personalised prevention. In a curative context, interventions to strengthen resilience aim to boost recovery from cognitive decline. In care for people with dementia, resilience focused interventions can strengthen coping mechanisms to maintain functioning and wellbeing of the individual and their support network. A good example of improving resilience in the social and policy context is the introduction of age-friendly cities and dementia-friendly communities. Good care for people with cognitive decline requires a health and social care system that can adapt to changes in demand. Given the interdependency of resilience at micro-, meso- and macro-levels, an integrative socioecological perspective is required. Applying the concept of resilience in the field of cognitive decline opens new horizons for research to improve understanding, predicting, intervening on health and social care needs for the increasing population with cognitive decline.

No abstract

No abstract